Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE Reno for Nephropathy
NCT07187713Phase 4Recruiting
- Sponsor
- Ace Cells Lab
- Start
- Sep 2025
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in chronic kidney disease (CKD), sponsored by Ace Cells Lab. Primary endpoint: Change in Urinary Albumin-to-Creatinine Ratio at 12 weeks. Started Sep 2025; status: recruiting.
02
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07187713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187713.